Clinical review report Edoxaban (Lixiana)
Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has r...
| Autor principal: | |
|---|---|
| Autor Corporativo: | |
| Formato: | Libro electrónico |
| Idioma: | Inglés |
| Publicado: |
Ottawa, Ontario :
Canadian Agency for Drugs and Technologies in Health
2017.
|
| Materias: | |
| Ver en Biblioteca Universitat Ramon Llull: | https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820283106719 |
| Sumario: | Taken orally, Edoxaban is a highly selective, direct, and reversible inhibitor of factor Xa. It has a Health Canada indication for the treatment of venous thromboembolism (VTE) (deep vein thrombosis (DVT) and pulmonary embolism (PE)) and the prevention of recurrent DVT and PE. The manufacturer has requested that edoxaban be reimbursed according to the Health Canada indication. The objective of this report was to perform a systematic review of the beneficial and harmful effects of edoxaban for the treatment of VTE (DVT and PE), and for the prevention of recurrent DVT and PE. |
|---|---|
| Descripción Física: | 1 online resource (1 PDF file (ix, 88 pages)) : illustrations |
